Advancing Health Equity
At Exelixis, we know that clinical trial research doesn't always include participants from a diverse patient population.
We are dedicated to finding solutions that will increase the number of patients from underserved communities in all phases of clinical trials supported and sponsored by Exelixis.
There's Work to Do
Cancer is a disease that can affect anyone. However, it doesn’t affect all people the same.1 For example, cancer is the number one leading cause of death in Asian and Hispanic communities, compared to the number two cause of death among all Americans.2
Certain groups in the U.S. are more highly burdened by cancer due to their race, ethnicity, income level, or insurance coverage. Right now, cancer clinical trials do not include enough people from all of these communities.1
There is a lot of work to do, and we are just getting started. A first step is to ensure that all patients who are appropriate for clinical trials—regardless of income, insurance, race, or ethnicity—have the information they need to consider enrolling in a clinical trial.1
Cancer Clinical Trials Include
Few Black and Hispanic People
Hispanic and Black people with cancer are less represented in clinical trials compared to their representation in the overall U.S. population.3,4
Prostate Cancer Risk for Underrepresented Men
Prostate cancer is the most commonly diagnosed cancer among men in the United States.5
Black men are at an increased risk for developing and dying of prostate cancer compared to White men. In 2022, it is estimated that 41,600 Black men will be diagnosed with prostate cancer and more than 6,000 Black men are expected to die of the disease.6 Only 4% of men in prostate cancer clinical trials sponsored by pharmaceutical companies are Black, although Black men represent 15% of the prostate cancer population in the U.S.7
Lifetime Risk of Prostate Cancer by Ethnicity6,8
Is This Trial Right for You?
If you are living with metastatic castration-resistant prostate cancer, you may be eligible for our clinical trial.
Still unsure? Talk with your doctor about your treatment options. For trial-specific questions, please reach out to Exelixis Medical Information at 1-888-393-5494 or by emailing email@example.com. We can answer your questions associated with participating in the CONTACT-02 clinical trial.
If you’d like to learn more, here’s where to start:
To find out more about participating, download the CONTACT-02 discussion guide and talk to your doctor.Download
THE COMBINATION OF CABOZANTINIB AND ATEZOLIZUMAB IS NOT APPROVED FOR THE USE
UNDER INVESTIGATION IN THIS TRIAL. SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.